Background: The purpose of the presented work is to evaluate the last decade's experience in surgical management of central neurocytoma (CN) and elucidate on the treatment strategies and new options.
Methods: The current series consists of the remaining 125 patients (70 females and 55 males) operated on during the past decade from 2008 to 2018. Most tumors were resected through transcortical ( = 76, 61%), or transcallosal ( = 40, 32%) approaches. In 5 (4%) patients with predominantly posterior location of the tumor, non-dominant superior parietal lobule approach was utilized. Both approaches (transcortical + transcallosal) were used in 4 (3%) of cases. Seven consecutive patients with large CN underwent prophylactic intraventricular stenting to prevent hydrocephalus.
Results: Gross total resection was achieved in 45 patients (36%), subtotal resection (STR) in 40 (32%) cases. After surgery, 63 (50%) patients had neurocognitive problems, including disorientation, attention deficit, global amnesia, short-term memory deficits, and perceptual motor and social cognition problems. A total of 26 patients (21%) had postoperative hemorrhage in the resection bed. Obstructive hydrocephalus was noted in 25 (20%) patients. The entrapment of the occipital and/or temporal horns was observed in seven cases. None of the seven patients with prophylactic intraventricular stents required shunting.
Conclusion: Although high rates of gross total or STR can be expected, the mortality and morbidity remain significant even in the modern neurosurgical era. Prophylactic intraventricular stenting in patients with large posteriorly located tumors with hydrocephalus may prevent ventricular entrapment and shunting. The main risk factors for recurrence are presence of residual disease and Ki-67 index over 5%. Recurrent symptomatic tumors should be treated surgically, whereas asymptomatic progression can be managed with stereotactic radiosurgery. Both treatment modalities are associated with low risk of complications and high tumor control rates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326110 | PMC |
| http://dx.doi.org/10.25259/SNI_764_2020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mean Arterial Pressure and Neonatal Outcomes in Pregnancies Complicated by Mild Chronic Hypertension.
Obstet Gynecol
July 2024
Departments of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, and University of South Alabama at Mobile, Mobile, Alabama, University of North Carolina at Chapel Hill, Chapel Hill, and Duke University, Durham, North Carolina, University of Pennsylvania and Drexel University College of Medicine, Philadelphia, St. Luke's University Health Network, Bethlehem, Magee Women's Hospital and University of Pittsburgh, Pittsburgh, and Lehigh Valley Health Network, Allentown, Pennsylvania, University of Texas at Houston and Baylor College of Medicine and Texas Children's Hospital, Houston, and University of Texas Medical Branch, Galveston, Texas, Columbia University, New York, Winthrop University Hospital, Long Island, and New York Presbyterian Queens Hospital, Flushing, New York, University of Oklahoma, Oklahoma City, Oklahoma, MetroHealth System, Cleveland, The Ohio State University, Columbus, and Wright State University, Fairborn, Ohio, Indiana University, Indianapolis, Indiana, University of Utah Health, Salt Lake City, Utah, Christiana Care Health Services, Newark, Delaware, UnityPoint Health-Meriter Hospital/Marshfield Clinic, Madison, and Medical College of Wisconsin, Milwaukee, Wisconsin, Washington University in St. Louis, St. Louis, Missouri, University of Mississippi Medical Center, Jackson, Mississippi, Yale University, New Haven, Connecticut, University of Colorado, Aurora, and Denver Health Hospital, Denver, Colorado, Emory University, Atlanta, Georgia, University of California, San Francisco, San Francisco, and Stanford University, Stanford, California, Arrowhead Regional Medical Center/Beaumont Hospital, Detroit, Michigan, Virtua Health, Voorhees, New Jersey, Oregon Health & Science University, Portland, Oregon, University of Arkansas for Medical Sciences, Little Rock, Arkansas, University of Tennessee Health Science Center, Memphis, and Vanderbilt University Medical Center, Nashville, Tennessee, Tulane University, New Orleans, Louisiana, University of Kansas Medical Center, Kansas City, Kansas, and Medical University of South Carolina, Charleston, South Carolina; the Center for Women's Reproductive Health, the Department of Biostatistics, and the Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama; Penn State College of Medicine, Hershey, Pennsylvania; Intermountain Health, Salt Lake City, Utah; Ochsner Baptist Medical Center, New Orleans, Louisiana; St. Peters University Hospital and the Department of Obstetrics, Gynecology and Reproductive Health, New Jersey Medical School, Newark, and the Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Weill Cornell University, New York, New York; Zuckerberg San Francisco General Hospital, San Francisco, California; TriHealth, Cincinnati Children's Hospital, Cincinnati, Ohio; the Division of Cardiovascular Sciences, NHLBI, Bethesda, Maryland; and the Department of Women's Health, University of Texas at Austin, Austin, Texas.
Objective: To estimate the association between mean arterial pressure during pregnancy and neonatal outcomes in participants with chronic hypertension using data from the CHAP (Chronic Hypertension and Pregnancy) trial.
Methods: A secondary analysis of the CHAP trial, an open-label, multicenter randomized trial of antihypertensive treatment in pregnancy, was conducted. The CHAP trial enrolled participants with mild chronic hypertension (blood pressure [BP] 140-159/90-104 mm Hg) and singleton pregnancies less than 23 weeks of gestation, randomizing them to active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg) or standard treatment (control; antihypertensives withheld unless BP reached 160 mm Hg systolic BP or higher or 105 mm Hg diastolic BP or higher).
Pharmacologic Venous Thromboembolism Prophylaxis in Patients with Nontraumatic Subarachnoid Hemorrhage Requiring an External Ventricular Drain.
Neurocrit Care
December 2024
Department of Clinical Pharmacy, Emory Healthcare, Atlanta, GA, USA.
Background: Optimal pharmacologic thromboprophylaxis dosing is not well described in patients with subarachnoid hemorrhage (SAH) with an external ventricular drain (EVD). Our patients with SAH with an EVD who receive prophylactic enoxaparin are routinely monitored using timed anti-Xa levels. Our primary study goal was to determine the frequency of venous thromboembolism (VTE) and secondary intracranial hemorrhage (ICH) for this population of patients who received pharmacologic prophylaxis with enoxaparin or unfractionated heparin (UFH).
View Article and Find Full Text PDFProphylactic indomethacin and the risk of serious pulmonary hemorrhages in preterm infants less than 28 weeks' gestation.
J Perinatol
October 2024
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Objective: To determine if prophylactic indomethacin (PINDO) decreases serious pulmonary hemorrhages in infants <28 weeks.
Study Design: Intention-to-treat analysis of 615 consecutively admitted infants during four alternating protocol-driven epochs of PINDO or expectant patent ductus arteriosus (PDA) management.
Results: 41/615 (6.
Prophylactic effects of cyclooxygenase inhibitor on intraventricular hemorrhage: Effect modification by the risk of intraventricular hemorrhage.
Pediatr Neonatol
July 2024
Division of Neonatology, Center of Maternal-Fetal Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.
Cochrane Database Syst Rev
January 2024
Central Clinical School, School of Medicine, The University of Sydney, Sydney, Australia.
Background: Laryngeal mask airway surfactant administration (S-LMA) has the potential benefit of surfactant administration whilst avoiding endotracheal intubation and ventilation, ventilator-induced lung injury and bronchopulmonary dysplasia (BPD).
Objectives: To evaluate the benefits and harms of S-LMA either as prophylaxis or treatment (rescue) compared to placebo, no treatment, or intratracheal surfactant administration via an endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) or extubate at standard criteria (S-ETT) or via other less-invasive surfactant administration (LISA) methods on morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome (RDS).
Search Methods: We searched CENTRAL, MEDLINE, Embase, CINAHL, and three trial registries in December 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!